Consistent with these findings, SEL24-B489 was more active against primary FLT3-WT and FLT3-ITD peripheral AML cells and CD34+ bone marrow blasts than either of the selective inhibitors (Figure 1B and 1C, respectively). This evidence concerns the gene FLT3 and acute myeloid leukemia.